Author(s): Shwetlana Shambharkar, Rani Tonde, Shraddha Nilkhan, Sakshi Charhate, Wajid Ahmad.

Email(s): sshwetlana1025@gmail.com

DOI: 10.52711/2231-5713.2024.00005   

Address: Shwetlana Shambharkar*, Rani Tonde, Shraddha Nilkhan, Sakshi Charhate, Wajid Ahmad
Department of Pharmaceutical Chemistry, P. R. Pote Patil College of Pharmacy, Amravati – 444602.
*Corresponding Author

Published In:   Volume - 14,      Issue - 1,     Year - 2024


ABSTRACT:
Remoglifozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remoglifozinetabonate (Remo™, Remozen™), the prodrug for remoglifozin, recently received its first approval as a treatment for type 2 diabetes mellitus (T2DM) in India. A sensitive, precise and stability-indicating high performance thin layer chromatographic (HPTLC) method has been developed for analysis of Remogliflozin Etabonate in tablet formation. Type and diabetes mellitus (T&PM) is an emerging epidemic in Asian countries, especially in India. Remogliflozin Etabonate is the latest addition to the SGTL2 inhibitor class of drug that have been recently appeared in India for management of T2DM. Remogliflozin Etabonate is a potent an selective inhibitor of SGLT2 with the unique distinction of being administered as a prodrug exitstence of active metabolities and short half-live necesstating twice daily dosing. The phase III study of Remogliflozin Etabonate demostrated it to be an efficacious and safe agent and remogliplgin a selective O-linked glycocide inhibitor of SGLT2, Remogliflozin Etabonate increase urine glucose excration and reduces plasma glucose concentration and decreased body weight. Remogliflozinetabonate shows Maximum Absorbance at 229nm. Beer’s law was obeyed in range of 2-10µg/ml. The correlation coefficient was found to be 0.9990. The result of interday and intraday precision shows standard deviation ranging from 0.050% - 0.254% and 0.058% - 0.258% for three concentration and three replicates. The Percentage recovery was found to be in the range of 98.94% - 99.86%. The LOD and LOQ were found to be 0.037µg/ml and 0.113µg/ml respectively. The purposed method was novel and successfully applied for the determination of Remogliflozin Etabonate in Tablet Dosage Form.


Cite this article:
Shwetlana Shambharkar, Rani Tonde, Shraddha Nilkhan, Sakshi Charhate, Wajid Ahmad. Remogliflozin Etabonate (Re) the Latest Addition to the SGLT2 Inhibitor. Asian Journal of Pharmacy and Technology. Tech. 2024; 14(1):16-2. doi: 10.52711/2231-5713.2024.00005

Cite(Electronic):
Shwetlana Shambharkar, Rani Tonde, Shraddha Nilkhan, Sakshi Charhate, Wajid Ahmad. Remogliflozin Etabonate (Re) the Latest Addition to the SGLT2 Inhibitor. Asian Journal of Pharmacy and Technology. Tech. 2024; 14(1):16-2. doi: 10.52711/2231-5713.2024.00005   Available on: https://ajptonline.com/AbstractView.aspx?PID=2024-14-1-5


REFERENCE:
1.    A selective inhibitor of sodium-glucose cotransporter subtype 2 (SGLT2), which is to be administered as Remoglifozin Etabonate (Remo™, Remozen™), the prodrug for Remoglifozin, and is being developed for the treatment of type 2 diabetes mellitus (T2DM). Inhibition of SGLT2 (which is selectively expressed in the kidney).
2.    Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, MacLauchlin CC.  Assessment of remogliflozin etabonate, a sodium-dependent glucoseco-transporter-2 inhibitor, as a perpetrator of clinical drug interactions: a study on drug transporters and metabolic enzymes. 2012.
3.    J Diabetes Metab. Sigafoos JF, Bowers GD. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2: evidence from in vitro, human mass balance, and keto conazole interaction studies. Drug Metab Dispos. 2012; 40(11): 2090–2101. https://doi.org/10.1124/dmd.112.047258
4.    Tayade AB, Patil AS, Shirkhedkar AA. Development and validation of Zero order UV-spectrophotometric method by area under curve technique high performance thin layerchromatography for the estimation ofRemogliflozin etabonate in bulk and in house tablets. Invents Rapid: PharmAnalQual Assurance. 2019; 3:1–5
5.    Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res ClinPract 2010; 87(1): 4e14.
6.    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centeredApproach: position statement of the American Diabetes Association (ADA)And the European Association for the Study of Diabetes (EASD). Diabetes Car. 2012 ;35(6):1364e79.
7.    Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Global Partnership for Effective Diabetes Management. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract Suppl. 2007; 157:47e57
8.    Tamez-Perez HE, Gonzalez-Guajardo EE, Tamez-Pena AL. Consensus statement by The American Association Of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetesManagement algorithm – 2019 executive summary. Endocr Pract. 2019; 25(6): 622.  
9.    Choi CI. Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation Antihyperglycemic agents. Molecules. 2016; 21.
10.    Graham GG, Punt J, Arora M, Day R, Doogue MP, Duopng JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical Pharmacokinetics of Metformin. 2011; 50: 81
11.    Malviya VR, Tawar MG. Preparation and evaluation of oral dispersible strips of teneligliptin hydrobromide for treatment of diabetes mellitus. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020; 13(1): 4745-52.
12.    Waller DG, Sampson AP, Renwick AG, Hiller K. Medical Pharmacology and Therapeutics; 4th Edn, 457.
13.    Malviya V. Design and Characterization of Thermosensitive Mucoadhesive Nasal Gel for Meclizine Hydrochloride. International Journal of Pharmaceutical Sciences and Nanotechnology. 2022; 15(1): 5782-93.
14.    Tripathi, KD. Essential of Medical Pharmacology; 7th Edn; Jaypee Brothers Medical Publisher Pvt. Ltd. New Delhi, 2013; 258.
15.    Shethi PD. HPLC-Quantitative Analysis of Pharmaceutical Formulations. CBS Publishers and Distributers, New Delhi, 1996; 3-46.
16.    Chatwal GR. Instrumental Method of Chemical Analysis. Part-1, Himalaya Publishing House, 5th Editions.
17.    Fujimori Y, Katsuno Y, Nakashima I. Remogliflozinetabonate, in a novel category of selective Low affinity sodium glucose cotransporter inhibitors, exhibit antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008; 327(1): 268-276. https://doi.org/10.1124/jpet.108.140210
18.    Malviya V, Ladhake V, Gajbiye K, Satao J, Tawar M. Design and characterization of phase transition system of zolmitriptan hydrochloride for nasal drug delivery system. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020; 13(3): 4942-51.
19.    ChEMBL.  Remogliflozin etabonate.  https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2028665/. Accessed 18 Sept 2019. 4.  Product information of remogliflozin A by Cayman Chemicals, Accessed 18 Sept 2019.
20.    Zheng Y, Ley SH, Hu FB. Global actiology and epidemiology of type 2 diabetes mellitus and its Complications. Nat Rev Endocrinol. 2017: 14(2): 88. Doi: 10.1038/nrendo 2017.151.
21.    Malviya V, Tawar M, Burange P, Bairagi R. Preparation and Characterization of Gastroreten-tive Sustained Release In-situ Gel of Lafutidine. International Journal of Pharmaceutical Sciences and Nanotechnology. 2022; 15(6): 6216-28.
22.    International Diabetes Federation. IDF diabetes atlas 9th edition; 2019.
23.    Vidhi D, Patel P. Method development and validation of UV spectrophotometric estimation of remogliflozin etabonate in bulk and its tablet dosage form. Research Journal of Pharmacy and Technology. 2021; 14(4): 2042-4.
24.    Malviya V, Tawar M, Burange P, Bairagi R, Bhadange V, Vikhar C. Euphorbia neriifolia L. phytochemical lead compounds discovered using pharmacoinformatic methods as possible SARS CoV-2 main protease inhibitors. Journal of Research in Pharmacy. 2023; 27(1).
25.    Srinivasan R, Ahamed CS. Validation of Developed Analytical Methods for the Determination of Remoglifozin and Ertuglifozin in Pharmaceutical Dosage Forms-An Updated Review.
26.    Malviya V, Pande S. Development and Evaluation of Fast dissolving Film of Fluoxetine hydrochloride. Research Journal of Pharmacy and Technology. 2021;14(10):5345-50.
27.    Chaudhary A, Singh BK. Method Development and Validation for simultaneous Quantification of Remogliflozin and Metformin in Bulk and Tablets by RP-HPLC. Research Journal of Pharmacy and Technology. 2022; 15(10): 4709-14.
28.    Malviya V, Arya A, Burange P, Gajbhiye K, Rathod G, Tawar M. To evaluate the cardioprotective effect of hydroalcoholic extract of Matricaria chamomilla linn in isoproterenol induced myocardial infarction in wistar rats. Research Journal of Pharmacy and Technology. 2022; 15(9): 3887-92.
29.    Sriram S, Elizabeth AA, Akila L. Cost Analysis of SGLT2 Inhibitors in patients with type 2 Diabetes in India. Research Journal of Pharmacy and Technology. 2020; 13(12): 5861-5.
30.    Malviya V, Thakur Y, Gudadhe SS, Tawar M. Formulation and evaluation of natural gum based fast dissolving tablet of Meclizine hydrochloride by using 3 factorial design 2. Asian Journal of Pharmacy and Pharmacology. 2020; 6(2): 94-100.
31.    Nandhidha R, Punnagai K. Evaluation of anti-inflammatory and wound healing potential of sodium glucose co-transporter2 (SGLT2) inhibitors. Research Journal of Pharmacy and Technology. 2022; 15(10): 4457-62.
32.    Malviya, Vedanshu, Mukund Tawar, Prashant Burange, and Rahul Jodh. A brief review on resveratrol. 2022: 157-162.
33.    Suryadi A, Siswodihardjo S, Widiandani T, Widyowati R. Structure modifications of pinostrobin from Temu Kunci (Boesenbergia pandurata ROXB. SCHLECHT) and their analgesic activity based on in silico studies. Research Journal of Pharmacy and Technology. 2021; 14(4): 2089-94.
34.    Dave VS, Patel PU. Development and validation of simultaneous estimation of canagliflozin and metformin by Q absorbance ratio method in its API and tablet formulation. Research Journal of Pharmacy and Technology. 2022; 15(10): 4637-40.
35.    Malviya V, Burange P, Thakur Y, Tawar M. Enhancement of Solubility and Dissolution Rate of Atazanavir Sulfate by Nanocrystallization. Indian Journal of Pharmaceutical Education and Research. 2021; 55(3): S672-80.
36.    Malviya VR, Pande SD, Bobade NN. Preparation and evaluation of sustained release beads of zolmitriptan hydrochloride. Research Journal of Pharmacy and Technology. 2019; 12(12): 5972-6.
37.    Malviya V, Manekar S. Design, development, and evaluation of aceclofenac and curcumin agglomerates by Crystallo Co-Agglomeration technique. Research Journal of Pharmacy and Technology. 2021; 14(3): 1535-41.
38.    Malviya V. Preparation and Evaluation of Emulsomes as a Drug Delivery System for Bifonazole. Indian journal of Pharmaceutical Education and Research. 2021; 55(1): 86-94.
39.    Malviya VR, Pande SD. Road CKN. Preparation ad Evaluation of Zolmitriptan Hydrochloride Lozenge. J Pharma Res. 2019; 8(8): 624-9.
40.    Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin etabonate in the treatment of type 2 diabetes: design, development, and place in therapy. Drug Design, Development and Therapy. 2020: 2487-501.
41.    Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. Journal of Pharmacology and Experimental Therapeutics. 2008; 327(1): 268-76.
42.    Hussey EK, Kapur A, O’Connor-Semmes R, Tao W, Rafferty B, Polli JW, James CD, Dobbins RL. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacology and Toxicology. 2013; 14(1): 1-1.
43.    Dobbins RL, O’Connor‐Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, Tao W, Hussey EK. Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes, Obesity and Metabolism. 2012; 14(1): 15-22.




Recomonded Articles:

Author(s): Ruchika Sharma, M. S. Ashawat, C. P. S Verma, Neha Kumari

DOI: 10.5958/2231-5713.2020.00039.2         Access: Open Access Read More

Author(s): Sayali S. More, Sandeep S. Sonawane, Santosh S. Chhajed, Sanjay J. Kshirsagar

DOI: 10.5958/2231-5713.2018.00023.5         Access: Open Access Read More

Author(s): S. Kathirvel, R. Raju, B. Seethadevi, A. Suneetha, J. Pavani

DOI:         Access: Open Access Read More

Author(s): P. Swathi, K. Rajeswar Dutt, K. N. V Rao, M. Alagar Raja

DOI: 10.5958/2231-5713.2017.00025.3         Access: Open Access Read More

Author(s): Tentu Nageswara Rao, A. Vijayalakshmi, Karri Apparao, N. Krishnarao

DOI: 10.5958/2231-5713.2017.00024.1         Access: Open Access Read More

Author(s): S. Rawat, Akhilesh Gupta

DOI:         Access: Open Access Read More

Author(s): Tanushree Chatterjee, Pradeep Kumar Sahu, Shilpi Chatterjee, Jai Godheja

DOI:         Access: Open Access Read More

Author(s): Sathyaseelan Thennarasan, Subbiah Murugesan, Vajiravelu Sivamurugan

DOI: 10.5958/2231-5713.2017.00026.5         Access: Open Access Read More

Author(s): G. Kumaraswamy, Gandla Lalitha, K. Swetha, R. Suthakaran, G. Ramesh Babu

DOI:         Access: Open Access Read More

Author(s): M. Kranthi Kumar Reddy, B. Narasimha Rao , K. Ravindra Reddy.

DOI:         Access: Open Access Read More

Author(s): Gandla. Kumara Swamy, JM Rajendra Kumar, J.V.L.N. Seshagiri Rao

DOI:         Access: Open Access Read More

Author(s): Amiza, Ghazala Yaseen, Sammia Shahid

DOI: 10.5958/2231-5713.2020.00036.7         Access: Open Access Read More

Author(s): Rucha A Patel, Meghna P Patel, Hasumati Raj, Nehal Shah

DOI: 10.5958/2231-5713.2015.00023.9         Access: Open Access Read More

Author(s): Virani Paras, Sojitra Rajanit, Savaj Bhadresh, Raj Hashumati, Jain Vineet, Patel Kalpesh, SutariyaVishnu

DOI: 10.5958/2231-5713.2015.00025.2         Access: Open Access Read More

Author(s): Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee

DOI: 10.52711/2231-5713.2021.00023         Access: Open Access Read More

Asian Journal of Pharmacy and Technology (AJPTech.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5713 


Recent Articles




Tags